• Home
  • » 
  • Reports
  • » 
  • Investor Series: Opportunities in RNA Th...

Opportunities in RNA Therapeutics Market

Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity and Company Valuation, Financial Analysis and Business Risk Assessment of Key Public Ventures, Market Forecast and Opportunity Analysis, Analysis of Returns on Investment, Key Acquisition Targets

  • Lowest Price Guaranteed From USD 1,899

  • Published
    March 2023

  • Pages
    174

  • View Count
    9266

  • Buy Now

Example Insights

Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Context-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Key-Industry-Players-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Innovators-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Distribution-by-Type-of-Therapy-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Early-Stage-Ventures-thumb
Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Value-Proposition-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Competitiveness-Analysis-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Key-Trends-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Public-Offerings-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Analysis-of-Investments-thumb
Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Parameters-Assessed-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Fundamental-Financial-Analysis-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Technical-Financial-Analysis-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Key-Indicators-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Stock-Price-Analysis-thumb
Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Financial-Overview-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Distribution-by-Therapeutic-Area-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Likely-Acquisition-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Key-Risks-Identified-thumb Investor-Series-Opportunities-in-RNA-Therapeutics-Market-Returns-on-Investment-thumb

Report Description

RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. These therapies are currently being developed using different types of RNA-based molecules, including coding RNAs (such as mRNA) and non-coding RNAs (such as interfering RNAs (RNAi), antisense oligonucleotides (ASO) and RNA aptamers). The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. However, despite the potential benefits offered by this therapeutic modality, the unique challenges associated with drug delivery, manufacturing, logistics and storage led to a decline in the popularity of RNA therapies post the initial rise in early 2000s. Consequently, some activity in this domain was reported in 2018, when ONPATTRO (developed by Alnylam Pharmaceuticals) received approval from USFDA and EMA; this RNAi therapy was intended for the treatment of hereditary transthyretin amyloidosis (hATTR), a rare and life-threatening disorder. Subsequently, it was the phenomenal success of mRNA therapies against the COVID-19 pandemic which fully reignited the interest of general public, patients, healthcare providers and investors in this market. For instance, in 2021 and 2022, two mRNA vaccines intended for COVID-19 received emergency use approvals from the USFDA; these were BNT162b2 (developed by BioNTech and Pfizer) and mRNA-1273 (developed by Moderna). In addition, RNA therapeutics have shown promising results in the treatment of rare diseases, particularly neurological and hepatic diseases. In fact, 80% of such therapies being evaluated in late stages of clinical development have received the orphan drug designation. This further showcases the potential of RNA therapeutics to actualize the concept of personalized medicine in the foreseen future.

RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein function and broaden the range of druggable targets, thereby, paving way for new avenues in disease diagnosis and treatment. Foreseeing these opportunities, numerous start-ups have been established in the last few years, indicating the growing interest in this sector. Owing to the rising demand for better therapeutic options and increasing adoption rate of such therapies, the investment focus for RNA therapeutics has increased significantly. In fact, since 2011, a total of over USD 16 billion was raised by RNA-based drug developers to advance their pipeline candidates. It is worth highlighting that, amongst the RNA therapeutics investors, majority of the investments have been led by mRNA vaccines investors and mRNA therapeutics investors. This is followed by RNAi therapeutics investors and RNA aptamers investors. Driven by the rise in government initiatives for early commercialization of pipeline therapeutics and active involvement of RNA therapeutics investors, we anticipate a variety of novel RNA based therapeutics to be developed, presenting lucrative investment opportunities for both short- and long-term investors.

Scope of the Report

The Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity and Company Valuation, Financial Analysis and Business Risk Assessment of Key Public Ventures, Market Forecast and Opportunity Analysis, Analysis of Returns on Investment, Key Acquisition Targets) report provides detailed information on the RNA therapeutics market, covering the various types of RNA therapeutics, including RNAi therapies, RNA aptamers, and mRNA therapies and mRNA vaccines. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, till 2035. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:

  • An introduction to RNA therapeutics, highlighting information on products that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of RNA therapies, and the opinions of representatives from key stakeholder companies involved in this domain.
  • A detailed analysis of RNA therapeutics focused companies that were established post-2007, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size and type of venture.
  • An assessment of the various products, offered by innovator companies engaged in this domain, based on number of products and type of product. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on basic company details, product portfolio, financing activity, estimated revenues and profits) of different innovator companies, using  a proprietary scoring criterion, which was informed via secondary research.
  • An informed perspective on the value proposition of companies captured in the report based on multiple relevant aspects, namely therapy-related aspect, developer-related aspect, technology-related aspect, and patient-related aspect.
  • A company competitiveness analysis, highlighting a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of RNA therapeutics. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of innovator companies mentioned in the report. Further, it features a list of leading investors in RNA therapeutics market, based on their participation in financing activity in this industry segment.
  • A proprietary analysis defining a basis for estimating the relative valuation of private companies, among the innovators discussed in this report. The value statements generated under this analytical framework were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated to generate the likely valuation estimates for all companies in the dataset.
  • An elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
  • Elaborate profiles of the prominent public ventures engaged in the development of RNA therapeutics, featuring a brief overview of the company, details on its management team, insights generated from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).
  • A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).
  • A detailed market forecast analysis, highlighting the likely evolution of the RNA therapeutics market in the short to mid-term and long term, over the period 2023-2035. Further the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • A case study where investors have exited various RNA therapeutics-related ventures, offering insights on returns on investment received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the key advantages offered by RNA therapies and vaccines? 
  • Which drugs are being evaluated across early and late stages of pipeline?
  • Which are the key therapeutic areas targeted by RNA therapeutics
  • What type of therapies that are being offered by the innovator companies?
  • What are the key value propositions offered by players engaged in the RNA therapeutics domain?
  • What is the relative competitiveness of different players engaged in the development of RNA therapeutics?
  • Who are the key investors that are actively supporting the development and commercialization of RNA therapeutics?
  • What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape?
  • Who are the potential acquisition targets for investors in the RNA therapeutics domain?
  • What are the major risks for investors seeking to tap into the RNA therapeutics domain?
  • What is the estimated return on investments received by the investors?
  • How is the current and future market opportunity related to RNA therapeutics likely to be distributed across key market segments?

Contents

Chapter Outlines

EXCEL DELIVERABLE

Spreadsheet I include details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. In addition, the deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated. 

Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights related to the capital investments made in the RNA therapeutics domain (since 2011).

Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed a proprietary model to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company. 

Spreadsheet IV is a collection of multiple MS Excel sheets that provides summary of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset.

Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, industry specific risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.

Spreadsheet VI includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on the likely returns on investments received by the mentioned investors.

Spreadsheet VII is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the RNA therapeutics market.

POWERPOINT DELIVERABLE

Chapter 1 provides a brief summary of the content presented in the report, beginning with the trends associated with the rapidly growing RNA therapeutics market. Further, some of the key benefits associated with RNA therapeutics, have been presented. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years. 

Chapters 2 and 3 features a brief (pictorial) summary of the project objectives and approach used for data collection and analysis, in this study. 

Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.

Section I: Introduction to RNA Therapeutics and Innovators Landscape
Chapter 5 presents an introduction to RNA therapeutics, highlighting the background about the origin and evolution of this domain, along with benefits of such therapies. It features the key application areas of RNA therapeutics and vaccines, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. Further, it includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives of key stakeholder companies (as stated in publicly available articles and validated through primary research). It concludes with a discussion on the prominent barriers to the development and success of RNA therapeutics. 

Chapter 6 focuses on some of the innovators (companies established post-2007) and features a detailed analysis of such companies. Further, this section highlights important company related details, such as year of establishment, headquarters, company size, and type of venture. 

Chapter 7 includes information on the various products developed by the companies captured in the report (listed in Chapter 6). Further, it features analysis based on number and types of therapy. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity and estimated revenues and profits) of the different innovator companies.

Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely therapy-related aspect, developer-related aspect, technology-related aspect and patient-related aspect, we developed an empirical framework to quantify the value proposition of a business.

Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developers of RNA therapeutics captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing and valuation exercise.

Section II: Analysis of Investments and Company Valuation
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report. 

Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated to generate valuation estimates for all companies in the dataset.

Section III: Financial Analysis and Assessment of Business Risks
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall RNA therapeutics market from a financial perspective and includes detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of publicly listed companies within the innovators landscape dataset. 

Chapter 13 includes detailed profiles of the prominent public ventures engaged in the development of RNA therapeutics. Each profile features a brief overview of the company, details on its management team, insights from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).

Chapter 14 includes a case study on business risk assessment, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).

Section IV: Market Forecast and Opportunity Analysis
Chapter 15 features an insightful market forecast and opportunity analysis, highlighting the estimated current and future size of the overall RNA therapeutics market, during the period 2023-2035. The opportunity has been segregated based on type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world).

Section V: Analysis of Returns on Investment and Key Acquisition Targets 
Chapter 16 includes a case study wherein the investors have exited various RNA therapeutics-based ventures, offering insights on returns on investment received (based on availability of data). The abovementioned estimates / details offer a perspective on how past investments have paid off for investors as company gradually went public, over time.

Chapter 17 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets. 

Chapter 18 provides a pictorial summary of the overall project, presenting insights on the market landscape, funding and investment activity, value proposition, key acquisition targets and the market opportunities in RNA therapeutics domain, across different global regions. 

Chapter 19 is a set of appendices, that contains the table of contents, list of figures, tables, companies and organizations mentioned in the report.

Table Of Contents

EXCEL DELIVERABLE

1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovators Landscape
1.3. Products Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. Appendices

2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in RNA Therapeutics
2.4 Appendices

3. COMPANY VALUATION ANALYSIS
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
3.4. Appendices

4. FUNDAMENTAL FINANCIAL ANALYSIS
4.1. Analysis Notes
4.2. Summary Dashboard
4.3. Company Fundamentals
4.4. Fundamental Analysis
4.4.1. Financial Ratios
4.4.4.1. Liquidity Ratios
4.4.4.2. Financial and Business Risk Ratios
4.4.4.3. Turnover / Efficiency Ratios
4.4.4.4. Profitability Ratios
4.4.4.4. Market Value Ratios
4.4.4.5. Stability Ratios
4.5. Appendices

5. TECHNICAL FINANCIAL ANALYSIS
5.1. Analysis Notes
5.2. Key Highlights
5.3. Open High Low Close Chart / Stock Price & Volume Traded (Last 100 Days)
5.4. 5 Day Moving Average (Buy & Sell Signals)
5.5. 10 Day Moving Average (Buy & Sell Signals)
5.6. 50 Day Moving Average (Buy & Sell Signals)
5.7. Bollinger Bands®
5.8. Relative Strength Index
5.9. Average Directional Index
5.10. Commodity Channel Index
5.11. Williams R
5.12. Moving Average Convergence Divergence (MACD)
5.13. Appendices

6. BUSINESS RISK ASSESSMENT
6.1. Analysis Notes
6.2. Business Risk Data
6.3. Appendices

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Analysis Notes
7.2. Market Forecast and Opportunity Analysis: Summary
7.3. Market Forecast and Opportunity Analysis: Base Scenario
7.4. Market Forecast and Opportunity Analysis: Conservative Scenario
7.5. Market Forecast and Opportunity Analysis: Optimistic Scenario

8. ANALYSIS OF RETURNS ON INVESTMENT
8.1. Analysis Notes
8.2. Estimated RoI for Investors in Company A
8.3. Estimated RoI for Investors in Company B
8.4. Estimated RoI for Investors in Company C

POWERPOINT DELIVERABLE 

1. CONTEXT

2. PROJECT APPROACH

3. PROJECT OBJECTIVES

4. EXECUTIVE SUMMARY

Section I: Introduction to RNA Therapeutics and Innovators Landscape 
5. THE RNA THERAPEUTICS MARKET
5.1. Overview
5.2. Types of RNA Therapeutics
5.3. Historical Development
5.4. Applications of RNA Therapeutics
5.5. Benefits of RNA Therapeutics
5.6. Challenges Associated with RNA Therapeutics
5.7. Contemporary Sentiments and Expert Opinions

6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE
6.1. Methodology
6.2. Innovators in the RNA Therapeutics Market
6.3. Analysis of Innovators Landscape
6.4. Concluding Remarks

7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of RNA Therapeutics
7.2. Analysis of Products Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing

8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Value Proposition Analysis: Therapy-related Aspect
8.3. Value Proposition Analysis: Developer-related Aspect
8.4. Value Proposition Analysis: Technology-related Aspect
8.5. Value Proposition Analysis: Patient-related Aspect
8.6. Concluding Remarks

9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks

Section II: Analysis of Investments and Company Valuation 
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. Funding and Investments Summary

11. COMPANY VALUATION ANALYSIS
11.1. Overview and Methodology
11.2. Valuation of Public Companies
11.3. Company Valuation: Based on Company Size
11.4. Company Valuation: Based on Latest Stage of Financing
11.5. Company Valuation: Based on Company Size and Latest Stage of Funding

Section III: Financial Analysis and Assessment of Business Risks 
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.2. Financial Ratios (Interpretation Guide)
12.3. Fundamental Financial Analysis: List of Public Companies
12.4. Case Study 1
12.5. Technical Financial Analysis Overview
12.6. Technical Indicators (Interpretation Guide)
12.7. Technical Financial Analysis: List of Public Companies
12.8. Case Study 2

13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Arbutus Biopharma
13.1.1. Key Highlights
13.1.1.1. Company Overview
13.1.1.2. Insights from Balance Sheet
13.1.1.3. Key Executive Team
13.1.1.4. Recent Developments

13.1.2. Key Financial Details
13.1.2.1. Company Investments
13.1.2.2. Company Fundamentals
13.1.2.3. Company Technicals

13.2. Arcturus Therapeutics
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Insights from Balance Sheet
13.2.1.3. Key Executive Team
13.2.1.4. Recent Developments

13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals

13.3. GreenLight Biosciences
13.3.1. Key Highlights
13.3.1.1. Company Overview
13.3.1.2. Insights from Balance Sheet
13.3.1.3. Key Executive Team
13.3.1.4. Recent Developments

13.3.2. Key Financial Details
13.3.2.1. Company Investments
13.3.2.2. Company Fundamentals
13.3.2.3. Company Technicals

13.4. Gritstone bio
13.4.1. Key Highlights
13.4.1.1. Company Overview
13.4.1.2. Insights from Balance Sheet
13.4.1.3. Key Executive Team
13.4.1.4. Recent Developments

13.4.2. Key Financial Details
13.4.2.1. Company Investments
13.4.2.2. Company Fundamentals
13.4.2.3. Company Technicals

13.5. IVERIC bio
13.5.1. Key Highlights
13.5.1.1. Company Overview
13.5.1.2. Insights from Balance Sheet
13.5.1.3. Key Executive Team
13.5.1.4. Recent Developments

13.5.2. Key Financial Details
13.5.2.1. Company Investments
13.5.2.2. Company Fundamentals
13.5.2.3. Company Technicals

13.6. Moderna
13.6.1. Key Highlights
13.6.1.1. Company Overview
13.6.1.2. Insights from Balance Sheet
13.6.1.3. Key Executive Team
13.6.1.4. Recent Developments

13.6.2. Key Financial Details
13.6.2.1. Company Investments
13.6.2.2. Company Fundamentals
13.6.2.3. Company Technicals

13.7. Omega Therapeutics
13.7.1. Key Highlights
13.7.1.1. Company Overview
13.7.1.2. Insights from Balance Sheet
13.7.1.3. Key Executive Team
13.7.1.4. Recent Developments

13.7.2. Key Financial Details
13.7.2.1. Company Investments
13.7.2.2. Company Fundamentals
13.7.2.3. Company Technicals

13.8. Phio Pharmaceuticals
13.8.1. Key Highlights
13.8.1.1. Company Overview
13.8.1.2. Insights from Balance Sheet
13.8.1.3. Key Executive Team
13.8.1.4. Recent Developments

13.8.2. Key Financial Details
13.8.2.1. Company Investments
13.8.2.2. Company Fundamentals
13.8.2.3. Company Technicals

13.9. Regulus Therapeutics
13.9.1. Key Highlights
13.9.1.1. Company Overview
13.9.1.2. Insights from Balance Sheet
13.9.1.3. Key Executive Team
13.9.1.4. Recent Developments

13.9.2. Key Financial Details
13.9.2.1. Company Investments
13.9.2.2. Company Fundamentals
13.9.2.3. Company Technicals

13.10. Vir Biotechnology
13.10.1. Key Highlights
13.10.1.1. Company Overview
13.10.1.2. Insights from Balance Sheet
13.10.1.3. Key Executive Team
13.10.1.4. Recent Developments

13.10.2. Key Financial Details
13.10.2.1. Company Investments
13.10.2.2. Company Fundamentals
13.10.2.3. Company Technicals

14. BUSINESS RISK ASSESSMENT
14.1. Overview and Methodology
14.2. Operations-related Risks
14.3. Business-related Risks
14.4. Financial / Asset-related Risks
14.5. Product / Technology-related Risks
14.6. Industry Specific Risks
14.7. Other Risks
14.8. Summary of Business Risk Assessment

Section IV: Market Forecast and Opportunity Analysis 
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Overview and Methodology
15.2. Global RNA Therapeutics Market, 2023-2035
15.2.1. RNA Therapeutics Market: Analysis by Type of Therapy, 2023 and 2035
15.2.1.1. RNA Therapeutics Market for miRNA Therapies, 2023-2035
15.2.1.2. RNA Therapeutics Market for siRNA Therapies, 2023-2035
15.2.1.3. RNA Therapeutics Market for mRNA Therapies, 2023-2035
15.2.1.4. RNA Therapeutics Market for mRNA Vaccines, 2023-2035
15.2.1.5. RNA Therapeutics Market for RNA Aptamers, 2023-2035

15.2.2. RNA Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
15.2.2.1. RNA Therapeutics Market for Infectious Diseases, 2023-2035
15.2.2.2. RNA Therapeutics Market for Metabolic Disorders, 2023-2035
15.2.2.3. RNA Therapeutics Market for Oncological Disorders, 2023-2035
15.2.2.4. RNA Therapeutics Market for Genetic Disorders, 2023-2035
15.2.2.5. RNA Therapeutics Market for Other Disorders, 2023-2035

15.2.3. RNA Therapeutics Market: Analysis by Route of Administration, 2023 and 2035
15.2.3.1. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035
15.2.3.2. RNA Therapeutics Market for Intravenous Therapies, 2023-2035
15.2.3.3 RNA Therapeutics Market for Intranasal Therapies, 2023-2035
15.2.3.4 RNA Therapeutics Market for Other Routes of Administration, 2023-2035

15.2.4. RNA Therapeutics Market: Analysis by Key Geographies, 2023 and 2035
15.2.4.1. RNA Therapeutics Market in North America, 2023-2035
15.2.4.2. RNA Therapeutics Market in Europe, 2023-2035
15.2.4.3. RNA Therapeutics Market in Asia, 2023-2035
15.2.4.3. RNA Therapeutics Market in Latin America, 2023-2035
15.2.4.3. RNA Therapeutics Market in Middle East and North Africa, 2023-2035
15.2.4.3. RNA Therapeutics Market in Rest of the World, 2023-2035

Section V: Analysis of Returns on Investment and Key Acquisition Targets 
16. ANALYSIS OF RETURNS ON INVESTMENT
16.1. Overview and Methodology
16.2. Case Studies
16.2.1. Avidity Biosciences
16.2.2. BioNTech
16.2.3. GreenLight Biosciences
16.2.4. Gritstone bio
16.2.5. IVERIC bio
16.2.6. Moderna
16.2.7. Regulus Therapeutics
16.2.8. Vir Biotechnology
16.3. Concluding Remarks

17. KEY ACQUISITION TARGETS
17.1. Overview
17.2. List of Key Acquisition Targets
17.3. Concluding Remarks

18. CONCLUSION

19. APPENDICES

List Of Figures

Figure 5.1. RNA Therapeutics: Key Definitions and Background
Figure 5.2. RNA Therapeutics: Types of Therapies and Key Industry Players
Figure 5.3. RNA Therapeutics: Key Historical Developments
Figure 5.4. RNA Therapeutics: Key Strategic Initiatives of Industry Players
Figure 5.5. RNA Therapeutics: Key Marketed Products and Current Unmet Needs
Figure 6.1. Innovators Landscape: Distribution by Year of Establishment
Figure 6.2. Innovators Landscape: Distribution by Type of Venture
Figure 6.3. Innovators Landscape: Distribution by Company Size
Figure 6.4. Innovators Landscape: Distribution by Geography
Figure 7.1. Products Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Products Landscape: Distribution by Type of Products
Figure 7.3. Products Landscape: Distribution of Products by Phase of Development
Figure 7.4. Products Landscape: Distribution of Products by Route of Administration
Figure 7.5. Products Landscape: Distribution of Products by Therapeutic Area
Figure 8.1. Therapy-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.2. Therapy-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.3. Developer-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.4. Developer-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.5. Technology-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.6. Technology-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.7. Patient-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.8. Patient-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.9. Summary of Value Proposition Analysis
Figure 9.1. Competitiveness Analysis: Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Companies based in Europe (Peer Group II)
Figure 9.3. Competitiveness Analysis: Companies based in Asia and Rest of the World (Peer Group III)
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, 2011-2022
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Distribution of Instances and Amount Invested by Region
Figure 10.5. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 10.6. Funding and Investment Analysis: Most Active Players by Amount Raised
Figure 10.7. Awards / Grants: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Distribution of Amount Invested by Region
Figure 10.9. Awards / Grants: Most Active Investors by Amount Invested
Figure 10.10. Seed Funding: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Distribution of Amount Invested by Region
Figure 10.12. Seed Funding: Most Active Investors by Amount Invested
Figure 10.13. Venture (Series A): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.14. Venture (Series A): Distribution of Amount Invested by Region
Figure 10.15. Venture (Series A): Most Active Investors by Amount Invested
Figure 10.16. Venture (Series B): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.17. Venture (Series B): Distribution of Amount Invested by Region
Figure 10.18. Venture (Series B): Most Active Investors by Amount Invested
Figure 10.19. Venture (Series C): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series C): Distribution of Amount Invested by Region
Figure 10.21. Venture (Series C): Most Active Investors by Amount Invested
Figure 10.22. Venture (Series D, E, F, G, H, and Unknown) Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series D, E, F, G, H, and Unknown): Distribution of Amount Invested by Region
Figure 10.24. Venture (Series D, E, F, G, H, and Unknown): Most Active Investors by Amount Invested
Figure 10.25. Public Offerings: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.26. Public Offerings: Distribution of Amount Invested by Region
Figure 10.27. Public Offerings: Publicly Listed Players
Figure 10.28. Private Placements: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.29. Private Placements: Distribution of Amount Invested by Region
Figure 10.30. Private Placements: Most Active Investors by Amount Invested
Figure 10.31. Debt Financing: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.32. Debt Financing: Distribution of Amount Invested by Region
Figure 10.33. Debt Financing: Most Active Investors by Amount Invested
Figure 10.34. Capital Investments in RNA Therapeutics: Summary of Investments, 2011-2022
Figure 12.1. Arbutus Biopharma: Annual Revenues and Key Balance Sheet Parameter-related Trends, 2017-2022
Figure 12.2. Arbutus Biopharma: Liquidity Ratios, 2017-2022
Figure 12.3. Arbutus Biopharma: Financial and Business Risk Ratios and Turnover / Efficiency Ratios, 2017-2022
Figure 12.4. Arbutus Biopharma: Profitability Ratios, 2017-2022
Figure 12.5. Arbutus Biopharma: Market Value Ratios and Stability Ratios, 2017-2022
Figure 12.6. Arcturus Therapeutics: Stock Price (Candlestick Chart) and Volume Traded
Figure 12.7. Arcturus Therapeutics: 5-Day Moving Average
Figure 12.8. Arcturus Therapeutics: 10-Day Moving Average
Figure 12.9. Arcturus Therapeutics: 50-Day Moving Average
Figure 12.10. Arcturus Therapeutics: Bollinger Band
Figure 12.11. Arcturus Therapeutics: Relative Strength Index
Figure 12.12. Arcturus Therapeutics: Commodity Channel Index (CCI)
Figure 12.13. Arcturus Therapeutics: Moving Average Convergence / Divergence (MACD)
Figure 12.14. Arcturus Therapeutics: Williams’ R Analysis
Figure 12.15. Arcturus Therapeutics: Average Directional Index (ADX)
Figure 13.1. Arbutus Biopharma: Company Fundamentals
Figure 13.2. Arbutus Biopharma: Trend of Stock Prices Since Initial Public Offering
Figure 13.3. Arcturus Therapeutics: Company Fundamentals
Figure 13.4. Arcturus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.5. GreenLight Biosciences: Company Fundamentals
Figure 13.6. GreenLight Biosciences: Trend of Stock Prices Since Initial Public Offering
Figure 13.7. Gritstone bio: Company Fundamentals
Figure 13.8. Gritstone bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.9. IVERIC bio: Company Fundamentals
Figure 13.10. IVERIC bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.11. Moderna: Company Fundamentals
Figure 13.12. Moderna: Trend of Stock Prices Since Initial Public Offering
Figure 13.13. Omega Therapeutics: Company Fundamentals
Figure 13.14. Omega Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.15. Phio Pharmaceuticals: Company Fundamentals
Figure 13.16. Phio Pharmaceuticals: Trend of Stock Prices Since Initial Public Offering
Figure 13.17. Regulus Therapeutics: Company Fundamentals
Figure 13.18. Regulus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.19. Vir Biotechnology: Company Fundamentals
Figure 13.20. Vir Biotechnology: Trend of Stock Prices Since Initial Public Offering
Figure 14.1. Business Risk Assessment: Operations-related Risks
Figure 14.2. Business Risk Assessment: Business-related Risks
Figure 14.3. Business Risk Assessment: Financial / Asset-related Risks
Figure 14.4. Business Risk Assessment: Product / Technology-related Risks
Figure 14.5. Business Risk Assessment: Industry Specific Risks
Figure 14.6. Business Risk Assessment: Other Risks
Figure 14.7. Summary of Business Risk Assessment
Figure 15.1. RNA Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 15.2. RNA Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 15.3. RNA Therapeutics Market for miRNA Therapies, 2023-2035 (USD Million)
Figure 15.4. RNA Therapeutics Market for siRNA Therapies, 2023-2035 (USD Million)
Figure 15.5 RNA Therapeutics Market for mRNA Therapies, 2023-2035 (USD Million)
Figure 15.6. RNA Therapeutics Market for mRNA Vaccines, 2023-2035 (USD Million)
Figure 15.7. RNA Therapeutics Market for RNA Aptamers, 2023-2035 (USD Million)
Figure 15.8. RNA Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 15.9. RNA Therapeutics Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 15.10. RNA Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 15.11. RNA Therapeutics Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 15.12. RNA Therapeutics Market for Genetic Disorders, 2023-2035 (USD Million)
Figure 15.13. RNA Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 15.14. RNA Therapeutics Market: Distribution by Route of Administration, 2023 and 2035
Figure 15.15. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035 (USD Million)
Figure 15.16. RNA Therapeutics Market for Intravenous Therapies, 2023-2035 (USD Million)
Figure 15.17. RNA Therapeutics Market for Intranasal Therapies, 2023-2035 (USD Million)
Figure 15.18. RNA Therapeutics Market for Other Routes of Administration, 2023-2035 (USD Million)
Figure 15.19. RNA Therapeutics Market: Distribution by Key Geographies, 2023 and 2035
Figure 15.20. RNA Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 15.21. RNA Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 15.22. RNA Therapeutics Market in Asia, 2023-2035 (USD Million)
Figure 15.23. RNA Therapeutics Market in Latin America, 2023-2035 (USD Million)
Figure 15.24. RNA Therapeutics Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.25. RNA Therapeutics Market in Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Avidity Biosciences: Returns on Investment Reported by Selected Stakeholdersand Historical Funding Activity
Figure 16.2. BioNTech: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.3. GreenLight Biosciences: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.4. Gritstone bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.5. IVERIC bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.6. Moderna: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.7. Regulus Therapeutics: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.8. Vir Biotechnology: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 17.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 17.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (I/IV)
Figure 17.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (II/IV)
Figure 17.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (III/IV)
Figure 17.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (IV/IV)
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia and Rest of the World

List Of Tables

Table 6.1. Key Innovators in the RNA Therapeutics Market
Table 7.1. Products Offered by Innovators in the RNA Therapeutics Market
Table 7.2. RNA Therapeutics Developers: Company Health Indexing (I/V)
Table 7.3. RNA Therapeutics Developers: Company Health Indexing (II/V)
Table 7.4. RNA Therapeutics Developers: Company Health Indexing (III/V)
Table 7.5. RNA Therapeutics Developers: Company Health Indexing (IV/V)
Table 7.6. RNA Therapeutics Developers: Company Health Indexing (V/V)
Table 11.1. Valuation of Public Companies: Sample Dataset
Table 11.2. Company Valuation: Based on Company Size
Table 11.3. Company Valuation: Based on Latest Stage of Financing
Table 11.4. Company Valuation: Based on Company Size and Latest Stage of Funding
Table 12.1. Fundamental Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 12.2. Technical Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 17.1. RNA Therapeutics Developers: Likely Acquisition Targets (Company Strength)
Table 17.2. RNA Therapeutics Developers: Likely Acquisition Targets (Value Proposition)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 8VC
  2. Abu Dhabi Investment Authority (ADIA)
  3. ACM Biolabs
  4. Advantech Capital
  5. AIM Vaccine 
  6. Alethea Capital Management
  7. Alexandria Venture Investments
  8. Alexion Pharmaceuticals
  9. Ally Bridge Group
  10. Alnylam Pharmaceuticals
  11. Alta Partners
  12. Amgen Ventures
  13. aptaTargets
  14. Arbutus Biopharma
  15. ARCH Venture Partners
  16. Arcturus Therapeutics
  17. ARIZ Precision Medicine
  18. ArrowMark Partners
  19. Ascletis Pharma
  20. AstraZeneca
  21. AT Impf
  22. Atlanta Therapeutics
  23. Atlas Venture
  24. Avidity Biosciences
  25. AyurMaya Capital Management
  26. Bain Capital Life Sciences
  27. Baird Capital
  28. Basking Biosciences
  29. BB Biotech Ventures
  30. Bill & Melinda Gates
  31. Bio-Matrix Scientific (BMSN)
  32. BioAxone BioSciences
  33. Biogen
  34. Biomedical Advanced Research and Development Authority (BARDA)
  35. BioNTech
  36. BIORCHESTRA
  37. BlueIO
  38. Boehringer Ingelheim Venture Fund
  39. Brace Pharma Capital
  40. Broadview Ventures
  41. Brookside Capital
  42. Builders Vision
  43. Caixa Capital Risc
  44. CanSino Biologics
  45. Casdin Capital
  46. CBC Group
  47. CDH Investments
  48. Centre for the Development of Industrial Technology (CDTI)
  49. Chimeron Bio
  50. China Growth Capital
  51. China Venture Capital
  52. Chong Kun Dang Pharmaceutical
  53. Clarus Life Sciences
  54. Colt Ventures
  55. Company K Partners
  56. Cormorant Asset Management
  57. Cowen
  58. CPE Yuanfeng Investments
  59. CR-CP Life Science Fund
  60. CureDuchenne
  61. Cystic Fibrosis Foundation
  62. Daily Partners
  63. Defense Advanced Research Projects Agency (DARPA)
  64. Dicerna Pharmaceuticals
  65. Domain Associates
  66. EcoR1 Capital
  67. EIT Health
  68. Eli Lilly
  69. EQT Life Sciences
  70. eTheRNA
  71. Ethris
  72. European Investment Bank
  73. European Union
  74. ExploRNA Therapeutics
  75. Fall Line Endurance
  76. Federated Hermes
  77. Fidelity Investments
  78. Flagship Pioneering
  79. Flanders Innovation & Entrepreneurship (VLAIO)
  80. Fortune Capital
  81. F-Prime Capital
  82. Frazier Healthcare Partners
  83. Fund+
  84. Future Industry Investment Fund
  85. Genmab
  86. German Federal Ministry of Education and Research
  87. GGV Capital
  88. Gilead Sciences
  89. GL Ventures
  90. Global Source Ventures
  91. Goldman Sachs
  92. GoldStone Investment
  93. GreenLight Biosciences
  94. Gritstone bio 
  95. GSK
  96. Guangzhou Sino-Israel Biotechnology Fund (GIBF)
  97. Guardian Therapeutics
  98. HBM Healthcare Investments
  99. Hercules Capital
  100. High-Tech Gründerfonds (HTGF)
  101. Hummingbird Ventures
  102. IMM Investment
  103. Immorna
  104. InnoRNA
  105. Innosuisse
  106. Innovate UK
  107. Insud Pharma
  108. Inveready
  109. Invus
  110. Ionis Pharmaceuticals
  111. IVERIC bio
  112. JAFCO 
  113. Janus Henderson Investors
  114. Julius Baer
  115. KB Investment
  116. Kernal Biologics
  117. Kiwoom Investment
  118. Kodiak Venture Partners
  119. Laureus Capital
  120. Leaps by Bayer
  121. LeBow Alpha
  122. Legend Capital
  123. Legend Star
  124. Lilly Asia Ventures
  125. Lincoln Park Capital
  126. Logos Capital
  127. Longmen Capital
  128. MassChallenge
  129. Medine
  130. MedLab Clinical
  131. Merck
  132. Mercurna
  133. MIG Material Innovative
  134. Ministry of Economy and Competitiveness
  135. Mirae Asset Capital
  136. miReven
  137. MLS Capital Fund II
  138. Moderna
  139. Moneta Ventures
  140. MOORE VENTURE PARTNERS
  141. Morningside VenturesSS
  142. MP Healthcare Venture Management
  143. MPM Capital
  144. Myeloid Therapeutics
  145. NanoDe Therapeutics
  146. National Center for Advancing Translational Sciences
  147. National Institute of Health (NIH)
  148. New Enterprise Associates (NEA)
  149. Novalis LifeSciences
  150. Novo Holdings
  151. OliX Pharmaceuticals
  152. Omega Fund
  153. Omega Therapeutics
  154. OrbiMed
  155. Oxford Bioscience Partners
  156. Oxford Finance
  157. Panlin Capital
  158. Pantherna Therapeutics
  159. Partner Fund Management
  160. Pavilion Capital
  161. Perceptive Advisors
  162. Pfizer
  163. Phio Pharmaceuticals (previously Rxi Pharmaceuticals)
  164. pHion Therapeutics
  165. Pictet
  166. PMV
  167. Point72
  168. Providence Therapeutics
  169. QianHai FOF
  170. Qianhai Fund of Funds
  171. Qiming Venture Partners
  172. RA Capital
  173. ReCode Therapeutics
  174. Redmile Group
  175. Regen BioPharma
  176. Regulus Therapeutics
  177. Rejuvenation Technologies
  178. Remeditex Ventures
  179. RENAP 
  180. Rev1 Ventures
  181. Ridgeback Capital
  182. Riesner Verwaltungs
  183. Rivas Capital
  184. RNACure
  185. RNAimmune 
  186. Roche
  187. Roivant Sciences
  188. RTW Investments
  189. S2G Ventures
  190. Samsara BioCapital
  191. Sangel Capital
  192. Sanofi
  193. Sequoia Capital
  194. Shinhan Capital
  195. Silenseed
  196. Silicon Valley Bank
  197. Sirnaomics
  198. Skyline Ventures
  199. Smilegate Investment
  200. SoftBank Vision Fund
  201. Soluventis
  202. SR One
  203. ST Pharm
  204. Stemirna Therapeutics
  205. Suzhou Ribo Life Science
  206. SV Life Sciences
  207. Symbiosis International (Deemed University)
  208. Takeda Pharmaceuticals
  209. Tao Capital Partners
  210. Tavistock Life Sciences
  211. Temasek
  212. Terra Magnum Capital Partners
  213. The Column Group
  214. TransCode Therapeutics
  215. Trinitas Capital Management
  216. Turn Biotechnologies
  217. Ultragenyx
  218. Venrock Healthcare Capital Partners
  219. Versant Ventures
  220. Vida Ventures
  221. Viking Global Investors
  222. Vir Biotechnology
  223. Viridian Therapeutics
  224. VitaDAO
  225. Vivo Capital
  226. Walvax Biotechnology
  227. Wellington Management
  228. Western Australian Institute for Medical Research (WAIMR)
  229. Ziphius Vaccines

Source 1: https://www.biopharminternational.com/view/the-covid-19-pandemic-and-its-positive-impact-on-rna-drug-development
Source 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627066/

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.